|
Antibiotic profile
|
No. of antibiotic groups
|
No. (%)
|
|---|
|
CTX/CAZ/CIP/LVX/Te/AM/SXT
|
5
|
19 (17.9)
|
|
CTX/CIP/LVX/Te/AM/SXT
|
5
|
8 (7.6)
|
|
CTX/CAZ/CIP/LVX/AM/SXT
|
4
|
2 (1.9)
|
|
CTX/ CAZ/CIP/LVX/Te/AM
|
4
|
1 (0.9)
|
|
CTX/CAZ/Te/AM/SXT
|
4
|
14 (13.2)
|
|
CTX/CIP/LVX/AM/SXT
|
4
|
2 (1.9)
|
|
CIP/LVX/Te/AM/SXT
|
4
|
4 (3.8)
|
|
CTX/Te/AM/SXT
|
4
|
12 (11.3)
|
|
CIP/Te/AN/SXT
|
4
|
1 (0.9)
|
|
CTX/CAZ/CIP/LVX/AM
|
3
|
1 (0.9)
|
|
CTX/CAZ/AM/SXT
|
3
|
6 (5.7)
|
|
CTX/CAZ/TZP/AM
|
3
|
1 (0.9)
|
|
CTX//CIP/LVX/AM
|
3
|
1 (0.9)
|
|
CIP/LVX/Te/SXT
|
3
|
1 (0.9)
|
|
CTX/Te/AM
|
3
|
4 (3.8)
|
|
CTX/AM/SXT
|
3
|
2 (1.9)
|
|
CIP/Te/AM
|
3
|
1 (0.9)
|
|
CIP/AM/SXT
|
3
|
1 (0.9)
|
|
LVX/Te/SXT
|
3
|
1 (0.9)
|
|
Te/AM/SXT
|
3
|
24 (22.7)
|
- AM ampicillin, AN amikacin, CAZ ceftazidime, CIP ciprofloxacin, CTX cefotaxime, LVX levofloxacin, STX trimethoprim + sulfamethoxazole, Te tetracyclines, TZP piperacillin + tazobactam, MDR multidrug resistant
